[Replay] The company behind the psychedelic revolution

Supported by original Sharks 🦈                                                                                                                                                                                                                                                                                                                                                                                                                 October 23, 2023 | [Read Online]( *Sponsored by Psycheceutical Bioscience Hey Folks, If you couldn’t watch it on October 19th, what a pity. My LIVE and exclusive interview with Chad Harman, CEO of [Psycheceutical Bioscience](, was dynamic, engaging, and deeply informative. The chatroom was abuzz with questions and Chad didn’t disappoint! Still, not all is lost. You can watch the recording [right here]( (or click on the image below). And based on the work that this company is doing – and the information Chad shared with us – I urge you to pay close attention. I think there’s a great investment opportunity here, what about you? Yep, that is Chad laughing at me trying to pronounce Psycheceutical – thank you Production Team. [Psycheceutical]( has been named a TOP Biotech Startup of 2023 by LifeSciences Review. Why? It’s using cutting-edge technology to bring psychedelics and pharmaceutics together so that the medical profession can be confident in prescribing these drugs to sufferers. It’s doing this by creating state-of-the-art drug delivery technology that enables the precise dosing required for the safe and effective treatment of depression, PTSD, anxiety, and a host of other mental health disorders. As Chad confirmed during our interview, the work that this company is doing is revolutionary… something Kevin Harrington of Shark Tank fame understands. He's an investor and strategic advisor to Psycheceutical. Talk about pulling out all the stops! The details that caught my attention the most during our time together include: - Psycheceutical is operating in a market of 300 million plus people suffering from depression, addiction, PTSD and other mental disorders. This number is only increasing because of the impacts COVID had on societies as well as the wars in Ukraine and Israel. (Stock traders – and even more so, investors – probably have PTSD as well, after how the markets have behaved since 2020!). - The company is well into its Phase 1 trials of its Neurodirect ketamine topical for the treatment of PTSD. What’s most exciting about this is that the trials are being conducted in Australia, where they closely follow the FDA guidelines while offering companies a 43.5% government rebate for their research! - In a breakthrough move in the psychedelic drugs space, Psycheceutical’s medicines and its patented delivery systems make it possible for doctors and nurse practitioners to prescribe it without any psychologist or psychiatric involvement! This significantly reduces the time and cost involved, making it more accessible to those who need it most. - It has TWO great revenue tracks: Licensing its drug delivery system and creating its own formulations. - And so much more! Even if you were able to watch this interview live on October 19, do yourself a favor and watch it again. There is just so much interesting and valuable information in here… not only for potential investors, but also for anyone with personal experience with mental disorders. Trading on the OTC as BWVI, Psycheceutical is conducting a [Reg CF campaign through Wefunder]( to further its research and development. This offering gives new investors favorable terms and a better entry price than simply going directly to the exchange. 👉Investors can grab exclusive “Friends Invest First” benefits, including a 25% discount to market, and can invest for as little as $250. This early bird offer is only available for a limited time (as I write this, you only have 11 days left to take advantage!!!). This means that you do NOT need to be an accredited investor to grab a seat on this train. Why is the company raising funds via a CF if it’s already public? I asked Chad about that. As he explains (in the video), they’re doing this to give a wider base of investors the opportunity to invest… and increasing the number of investors will allow the company to uplist to a bigger exchange. This move would have major benefits to all parties involved – the company, its investors, and sufferers of mental disorders seeking non-toxic, non-addictive solutions. So do a deep dive into this trailblazer, and besides the [Wefunder page]( you can access [their investor presentation here](. Here’s to YOUR success, *Sponsored content. Like all investments, this investment involves substantial risk. Please see full disclosures below.  Questions or concerns about our products? Email [Support@boardroominvesting.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) seventy five hundred dollars in total to run advertisements enhancing public awareness of the company. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Raging Bull strongly recommends you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. Update your email preferences or unsubscribe [here]( © 2023 Boardroom 62 Calef Hwy. #233 Lee, NH 03861, United States of America